Bulbine natalensis及其成分对CYP3A4和CYP2C9活性的调节:含该植物补充剂的HDI风险评估
Bulbine natalensis是非洲民间草药,作为膳食补充剂用于增强男性性功能和肌肉力量。本研究探讨其通过PXR介导诱导CYP3A4和CYP2C9及抑制催化活性的HDI潜力。结果显示其甲醇提取物激活PXR(EC50 6.2 ± 0.6 µg/ml),增加CYP3A4和CYP2C9 mRNA表达,并强烈抑制CYP2C9活性。提示与CYP3A4/CYP2C9底物药物合用可能存在HDI风险。
要点
- B. natalensis提取物激活PXR并诱导CYP3A4和CYP2C9表达
- Knipholone是最有效的PXR激活剂和CYP inducer
- 提取物及蒽醌类强烈抑制CYP2C9,对CYP3A4抑制弱
核心结论
- B. natalensis可能通过诱导CYP3A4和CYP2C9以及抑制CYP2C9活性而增加HDI风险。
- 与CYP3A4和CYP2C9底物药物合用时可能导致意外不良反应或治疗失败。
研究设计与样本
- 体外研究:使用HepG2细胞评估PXR激活和CYP酶表达与活性。
- 采用分子对接研究成分与PXR的结合特征。
- CYP抑制实验评估提取物及成分对CYP3A4和CYP2C9催化活性的影响。
主要发现
- B. natalensis甲醇提取物激活PXR,EC50为6.2 ± 0.6 µg/ml。
- 在30 µg/ml时,CYP3A4 mRNA表达增加2.40 ± 0.01倍,CYP2C9增加3.37 ± 0.3倍。
- Knipholone是最有效的PXR激活剂,EC50为0.3 ± 0.1 µM,其次是bulbine-knipholone(EC50 2.0 ± 0.5 µM)和6'-甲基knipholone(EC50 4.0 ± 0.5 µM)。
- Knipholone在10 µM时增加CYP3A4表达8.47 ± 2.5倍,CYP2C9表达2.64 ± 0.3倍。
- 提取物及蒽醌类强烈抑制CYP2C9催化活性,对CYP3A4抑制较弱。
临床怎么用
- 询问患者是否使用含B. natalensis的补充剂,尤其是与CYP3A4或CYP2C9底物药物合用时。
- 警惕可能的 herb-drug interaction 导致药物疗效降低或毒性增加。
局限性
- 研究仅为体外实验,需进一步研究验证这些发现并确立临床相关性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Bulbine natalensis is an African-folk medicinal plant used as a dietary supplement for enhancing sexual function and muscle strength in males by presumably boosting testosterone levels, but no scientific information is available about the possible herb-drug interaction (HDI) risk when bulbine-containing supplements are concomitantly taken with prescription drugs. PURPOSE: This study was aimed to investigate the HDI potential of B. natalensis in terms of the pregnane X receptor (PXR)-mediated induction of major drug-metabolizing cytochrome P450 enzyme isoforms (i.e., CYP3A4 and CYP2C9) as well as inhibition of their catalytic activity. RESULTS: We found that a methanolic extract of B. natalensis activated PXR (EC50 6.2 ± 0.6 µg/ml) in HepG2 cells resulting in increased mRNA expression of CYP3A4 (2.40 ± 0.01 fold) and CYP2C9 (3.37 ± 0.3 fold) at 30 µg/ml which was reflected in increased activites of the two enzymes. Among the constituents of B. natalensis, knipholone was the most potent PXR activator (EC50 0.3 ± 0.1 µM) followed by bulbine-knipholone (EC50 2.0 ± 0.5 µM), and 6'-methylknipholone (EC50 4.0 ± 0.5 µM). Knipholone was also the most effective in increasing the expression of CYP3A4 (8.47 ± 2.5 fold) and CYP2C9 (2.64 ± 0.3 fold) at 10 µM. Docking studies further confirmed the unique structural features associated with knipholones for their superior inductive potentials in the activation of PXR compared to other anthraquinones. In a CYP inhibition assay, the methanolic extract as well as the anthraquinones strongly inhibited the catalytic activity of CYP2C9 while, inhibition of CYP3A4 was weak. CONCLUSIONS: These results suggest that consumption of B. natalensis may pose a potential risk for HDI if taken with conventional medications that are substrates of CYP3A4 and CYP2C9 and may contribute to unanticipated adverse reactions or therapeutic failures. Further studies are warranted to validate these findings and establish their clinical relevancy.
引用
- Husain I, Manda V, Alhusban M, et al. Modulation of CYP3A4 and CYP2C9 activity by Bulbine natalensis and its constituents: An assessment of HDI risk of B. natalensis containing supplements. Phytomedicine. 2020. PMID: 33321412. doi:10.1016/j.phymed.2020.153416
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。